Amgen 2001 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 54

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54

of Sun Microsystems, Inc., and Frank
Biondi, senior managing director of
WaterView Advisors LLC, join our board
of directors.
Let me pause here to underscore just how
valuable an asset we have in Amgen’s nearly
8,000-strong workforce. The important
contributions and personal sacrifices made
each day by each of our staff members were
thrown into sharp relief on September 11,
when we lost Dora Menchaca in the horrific
attacks on New York and Washington D.C.
Dora was a dedicated and highly creative
member of our clinical research staff. She
was also a wonderful human being. Her loss
has been deeply felt at Amgen by all those
who worked with her. We have made a
significant contribution in Dora’s memory
to the new UCLA Medical Center Amgen
oncology wing.
Finally, and perhaps most exciting of all, at
year-end we announced plans to acquire
Immunex Corporation and, with it, a third
blockbuster therapeutic and a strong scien-
tific staff with leading research abilities
in inflammation.
Immunex is one of the most successful
biotechnology companies operating in our
industry today. Its first-to-market inflam-
mation biologic, ENBREL
®
(etanercept),
acts against tumor necrosis factor, a protein
that plays a key role in autoimmune
diseases such as rheumatoid arthritis. It
is a blockbuster therapeutic that has the
potential to generate product sales of more
than $3 billion annually by 2005. Together,
ENBREL
®
, EPOGEN
®
(Epoetin alfa),
NEUPOGEN
®
,Aranesp
™
, Kineret
™
, and
Neulasta
™
represent a product line unparal-
leled in our industry, and with significant
patent protection until 2012 and beyond.
Amgen and Immunex are a strong combi-
nation for several reasons. Strategically,
the transaction is expected to give Amgen
immediate leadership in inflammation
therapies and a world-class research organi-
zation in inflammation, while enhancing
our overall product portfolio. Financially,
the acquisition is expected to accelerate
our sales growth and increase adjusted
earnings-per-share growth by 2004.
With the completion of the proposed
Immunex acquisition, the potential now
exists for Amgen to more than double in
size in the next five years.
Growth on that scale will require increasing
levels of investment in human talent and
corporate capabilities, a rigorous process for
allocating resources, and a clear-eyed view
of our competitive stance in world markets.
We’ve made an excellent start. Look for
more in the years ahead. I am confident that
Amgen will make solid progress in 2002
towards our aspiration to be the world’s
best human therapeutics company.
Kevin W. Sharer
Chairman and
Chief Executive Officer
March 1, 2002
Amgen Values
5
●Be science-based
●Compete intensely and win
●Work in teams
●Create value for patients, staff, and stockholders
●Trust and respect each other
●Ensure quality
●Collaborate, communicate, and build consensus
●Be ethical